4 May 2022
Simmunext: where immunotherapy and chemistry meet
Simmunext is a company name made of three words describing the innovative approach Oncode Investigator Carl Figdor has developed to create polymers which can act as artificial antigen-presenting cells to stimulate the immune system to obtain a therapeutic response. The company is now ready for its journey to leverage this platform technology to bring novel cancer therapies to the clinic.
29 April 2022
Missing enzyme identified: how MATCAP works and affects brain development
Oncode Investigator Thijn Brummelkamp’s lab (NKI) previously identified Vasohibins as detyrosinating enzymes, but most cells contain detyrosinated microtubules even when the two Vasohibin genes are deleted. The team now identified MATCAP as a new enzyme involved in this process. Together with Oncode Investigator Anastassis Perrakis’ lab (NKI) they then showed how MATCAP works and how it engages with microtubules.
26 April 2022
Oncode Investigators Bas van Steensel, Daniel Peeper and Alexander van Oudenaarden receive ERC Advanced Grant
Bas van Steensel and Daniel Peeper (both NKI) receive 2.5 million euro each. Van Steensel will use the grant to explore our messy genome while Peeper will focus on reinvigorating anticancer T cells.
22 April 2022
Oncode finalizes Investigator Assessment in preparation for Phase 2
This year marks the final year of the first phase of Oncode Institute. Together with our funders, Oncode is working hard on putting together a new five-year plan to continue realizing our vision: outsmarting cancer, impacting lives. As a part of moving into Phase 2, Oncode Institute has been assessed by our International Advisory Board and International Review Committee. As part of the institute’s assessment, a large part of our 61 Oncode Investigator (OI) team has been evaluated.
14 April 2022
Growth Fund invests 325 million euros in Oncode-PACT to accelerate the development of cancer drugs
The National Growth Fund invests 325 million euros in the Oncode-PACT plan to accelerate the preclinical development process of cancer drugs. With this investment, Oncode-PACT will develop valuable drug candidates faster and cheaper and thus bring them to patients sooner. This will improve the quality of life of cancer patients while strengthening the future economic earning capacity of the Netherlands.
7 April 2022
Finally live: looking back at the single-molecule imaging masterclass
On Thursday, 24 March 2022, at the NKI, we finally held a live masterclass again! This was the first masterclass on location since November 2019: an event organized by Oncode Investigators Marvin Tanenbaum (Hubrecht Institute) and Tineke Lenstra (NKI) with a guest lecture by Lukas Kapitein (Utrecht University).
18 March 2022
Ruud Delwel’s experience with the NKI Robotics and Screening Center
Investing in (new) technologies and facilities - which are available to all Oncode researchers - is one of the ways in which Oncode contributes to breakthroughs in cancer research. The Oncode drug screening centres of expertise at the LUMC and the NKI are examples of such facilities. They provide Oncode researchers with advice and support to perform complex compound screens with the Drug Repurposing library. Oncode Investigator Ruud Delwel explains how he currently works with the drug screening center at the NKI.
17 March 2022
Oncode Investigators Louis Vermeulen and Marvin Tanenbaum receive ERC Consolidator Grant
Oncode Institute is proud to announce that Oncode Investigators Louis Vermeulen (Amsterdam AMC) and Marvin Tanenbaum (Hubrecht Institute) received the ERC Consolidator Grant. The ERC Consolidator Grants are awarded to outstanding researchers with at least seven and up to twelve years of experience after completing their PhD, and a scientific track record showing great promise.
10 March 2022
Shapeshifting cancer cells during liver metastasis formation
The groups of Oncode Investigators Hugo Snippert (UMC Utrecht), Jacco van Rheenen (Netherlands Cancer Institute) and Michiel Vermeulen (Radboud University), together with Onno Kranenburg (UMC Utrecht), Martijn Gloerich (UCM Utrecht) and Prisca Liberali (FMI, Basel) have characterized how a colorectal tumor cell evolves as soon as it metastasizes to the liver and delineated which events are critical to succeed. Their findings have been published in Cancer Research.
9 March 2022
Tumor cell produces faulty proteins, even without DNA errors
Tumor cells produce proteins with tiny changes, even without prior changes in their DNA code: a phenomenon that has never been shown before and that is specifically seen in tumors. These proteins are different from their normal counterparts so that they can activate the human immune system. And that could provide us with new leads for new types of immunotherapy against cancer, in which “cold” tumors are made “hot.” This is the latest discovery by Oncode Investigator Reuven Agami’s research group, published in Nature.
Scroll for more